Photos from Envato
Companies from these countries have 19 of the 28 assets worldwide.
South Korea and China are developing deliquent antibody conjugates (DACS), an emerging precision medicine targeted therapy, GlobalData said.
DAC development is still in its early stages globally, with 28 assets being in the pipeline. Among them, South Korean and Chinese companies are collectively called 19 assets.
“With these innovative assets, Korean and Chinese companies can attract and expand strategic collaboration with foreign players,” said Nadim Answer, a pharmaceutical analyst at GlobalData.
DAC aims to overcome the limitations of traditional antibody-drug conjugates (ADCs) by combining the specificity of antibodies with the potency of protein degraders.
“It's too early to comment on the clinical success of the course; however, it has attracted attention as a new field of research,” Anwer added.
Join the Healthcare Asia Magazine Community
Since you're here…
…You can promote your company with us and connect with your customers in a variety of ways. Our team can help you Dight and create advertising campaigns on print and digitally on this website and on print magazines.
We can also organize real-life or digital events for you and find thought leader speakers and industry leaders who can become your potential partners to attend. We also run a number of award programs that give you the opportunity to earn your achievements this year and you can join as a participant or sponsor.
Let us help you move your business forward with a good partnership!
